mRNA Lipid Nanoparticles Target Tau Tangles in Alzheimer’s

Scientists featured in Cell Reports Medicine have detailed the creation of a specialized lipid nanoparticle (LNP) designed to transport mRNA directly into neurons, aiming to prevent the buildup of tau aggregates and combat Alzheimer’s disease. Tau Aggregates and Amyloid Plaques in Alzheimer’s Patho

Scientists featured in Cell Reports Medicine have detailed the creation of a specialized lipid nanoparticle (LNP) designed to transport mRNA directly into neurons, aiming to prevent the buildup of tau aggregates and combat Alzheimer’s disease.

Tau Aggregates and Amyloid Plaques in Alzheimer’s Pathology

In Alzheimer’s disease, the accumulation of amyloid beta plaques in the spaces between neurons and the clumping of tau protein inside neurons stand out as defining characteristics. Emerging research indicates that tau aggregation within neurons might play a more pivotal role than amyloid beta deposits. Although certain experimental treatments have shown promise in breaking down these tau tangles once they form, the U.S. Food and Drug Administration (FDA) has not yet greenlit any such therapies for clinical use.

This particular study focuses on a unique enzyme called TRIM11, a ligase capable of naturally dismantling tau aggregates without requiring ATP for its activity. Interestingly, while TRIM11 levels are elevated in certain brain tumors, neurons engineered to produce higher amounts of this protein demonstrate enhanced resistance to tau clumping. Conversely, in patients with Alzheimer’s, TRIM11 expression is notably reduced. Developing drugs that can penetrate the blood-brain barrier (BBB) presents a major challenge, but recent advancements in LNPs carrying mRNA therapies have successfully achieved this feat.

Delivering mRNA Across the Blood-Brain Barrier

The research team engineered a novel LNP variant, dubbed PLNP, which emulates the structure of acetylcholine—a key neurotransmitter—to slip past the BBB and reach target cells. When applied to neuron and microglial cell cultures, PLNP proved far superior to unprotected mRNA, which showed minimal cellular uptake. The mRNA delivered via PLNP reached the cells’ cytosol intact, avoiding breakdown in lysosomes. Blocking choline uptake drastically reduced mRNA absorption, confirming that PLNP follows the anticipated acetylcholine-mimicking route.

Building on these findings, the scientists tested PLNP in wild-type Black 6 mice. Their formulation delivered almost 17 times more mRNA than conventional, non-targeted LNPs, as quantified through fluorescent reporter markers. This mRNA distribution was uniform across various brain regions in the mice.

Subsequent tests incorporated actual TRIM11 mRNA linked to a fluorescent tag. In vitro comparisons again highlighted PLNP’s superiority over standard LNPs in terms of delivery efficiency.

Crucially, the delivered TRIM11 mRNA exerted its intended effects: when co-administered with okadaic acid—a compound that induces tau-related damage—the treatment dramatically curtailed tau tangle formation. The TRIM11 protein produced by the cells was observed co-localizing with any remaining tau aggregates, underscoring its targeted action. These observations verify that PLNP-mediated TRIM11 delivery effectively targets and engages with tau aggregates inside SH-SY5Y and Neuro2A cells.

Promising Outcomes in Alzheimer’s Mouse Models

To assess real-world efficacy, the researchers injected PLNP into male mice genetically modified with three mutations predisposing them to Alzheimer’s-like symptoms. These animals typically exhibit pronounced tau tangles in their brains by approximately 7.5 months of age. Over two weeks, the mice received three PLNP doses, followed by evaluations of their behavior and brain pathology.

The outcomes were striking: PLNP-treated Alzheimer’s-prone mice performed indistinguishably from healthy wild-type controls in multiple assessments. They displayed a robust preference for novel objects, excelled in the Morris water maze navigation task, exhibited normal exploratory behavior in open-field tests, and built nests comparably to wild-type mice. These behavioral improvements held steady even three months post-treatment. Comparable benefits emerged when administering the therapy to younger mice at 5.5 months, prior to overt tau pathology onset.

Pathological markers of tau dysfunction, which proliferate in untreated mice of this strain, were virtually eliminated in the treated group. This included reductions in inflammatory signals like IL-6 and TNF-α; moreover, the typical overactivation of microglia was markedly subdued. These neuroprotective effects spanned key brain areas, such as the hippocampus and cerebral cortex. Collectively, the data illustrate that systemic PLNP delivery of TRIM11 mRNA potently diminishes insoluble tau aggregates and curbs neuroinflammation in an Alzheimer’s disease model.

This approach represents a compelling disease-modifying intervention, particularly for early-stage Alzheimer’s management. Nonetheless, the team acknowledges several caveats. The core experiments relied solely on male, genetically altered mice. Potential unintended consequences also warrant scrutiny, as tau protein serves normal physiological roles, and unchecked TRIM11 activity might influence beneficial tau forms beyond pathogenic aggregates. Future studies will incorporate aged animals, diverse disease models, and expanded biomarker analyses to further substantiate these results.